Search
Cardiolipin Biosynthesis CL(20:2(11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z)/16:0)
smpdb.ca/view/SMP0256190MetabolicPA is then transferred to the inner mitochondrial membrane to continue cardiolipin synthesis. … Second, the mitochondrial outer membrane enzyme glycerol-3-phosphate acyltransferase esterifies an acyl-group to the sn-1 position of sn-glycerol 3-phosphate to form 1-acyl-sn-glycerol 3-phosphate (lysophosphatidic
Cardiolipin Biosynthesis CL(22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/16:0/18:2(9Z,12Z))
smpdb.ca/view/SMP0287543MetabolicPA is then transferred to the inner mitochondrial membrane to continue cardiolipin synthesis. … Second, the mitochondrial outer membrane enzyme glycerol-3-phosphate acyltransferase esterifies an acyl-group to the sn-1 position of sn-glycerol 3-phosphate to form 1-acyl-sn-glycerol 3-phosphate (lysophosphatidic
Cardiolipin Biosynthesis CL(22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/16:0/20:2(11Z,14Z))
smpdb.ca/view/SMP0287721MetabolicPA is then transferred to the inner mitochondrial membrane to continue cardiolipin synthesis. … Second, the mitochondrial outer membrane enzyme glycerol-3-phosphate acyltransferase esterifies an acyl-group to the sn-1 position of sn-glycerol 3-phosphate to form 1-acyl-sn-glycerol 3-phosphate (lysophosphatidic
Cardiolipin Biosynthesis CL(22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(9Z)/16:1(9Z))
smpdb.ca/view/SMP0287758MetabolicPA is then transferred to the inner mitochondrial membrane to continue cardiolipin synthesis. … Second, the mitochondrial outer membrane enzyme glycerol-3-phosphate acyltransferase esterifies an acyl-group to the sn-1 position of sn-glycerol 3-phosphate to form 1-acyl-sn-glycerol 3-phosphate (lysophosphatidic
Cardiolipin Biosynthesis CL(22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z)/16:0)
smpdb.ca/view/SMP0287770MetabolicPA is then transferred to the inner mitochondrial membrane to continue cardiolipin synthesis. … Second, the mitochondrial outer membrane enzyme glycerol-3-phosphate acyltransferase esterifies an acyl-group to the sn-1 position of sn-glycerol 3-phosphate to form 1-acyl-sn-glycerol 3-phosphate (lysophosphatidic
Cardiolipin Biosynthesis CL(22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:2(11Z,14Z)/16:0)
smpdb.ca/view/SMP0287798MetabolicPA is then transferred to the inner mitochondrial membrane to continue cardiolipin synthesis. … Second, the mitochondrial outer membrane enzyme glycerol-3-phosphate acyltransferase esterifies an acyl-group to the sn-1 position of sn-glycerol 3-phosphate to form 1-acyl-sn-glycerol 3-phosphate (lysophosphatidic
Cardiolipin Biosynthesis CL(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/14:0/16:1(9Z))
smpdb.ca/view/SMP0287889MetabolicPA is then transferred to the inner mitochondrial membrane to continue cardiolipin synthesis. … Second, the mitochondrial outer membrane enzyme glycerol-3-phosphate acyltransferase esterifies an acyl-group to the sn-1 position of sn-glycerol 3-phosphate to form 1-acyl-sn-glycerol 3-phosphate (lysophosphatidic
Elivaldogene autotemcel
go.drugbank.com/drugs/DB16746Approved[A243691] Elivaldogene autotemcel works by delivering genes into the patient's body to produce functional ALDPs. … It is used to provide functional copies of human adrenoleukodystrophy protein (ALDP) in patients with adrenoleukodystrophy,[L39491] an X-linked genetic disorder characterized by missing or non-functional
Fosphenytoin
go.drugbank.com/drugs/DB01320ApprovedInvestigationalIts main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials. … It works by slowing down impulses in the brain that cause seizures.
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 SubstratesInfigratinib
go.drugbank.com/drugs/DB11886ApprovedInvestigationalWithdrawn[L34304] The FDA later announced the final withdrawal of the approval of infigratinib for this indication on May 16, 2024: This decision was based on the sponsor's request due to clinical trial recruitment … [A235174] On May 28, 2021, the FDA granted accelerated approval to infigratinib - under the market name Truseltiq - for the treatment of previously treated, unresectable locally advanced or metastatic
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates